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Abstract Over the last decade, understanding of glioma on
a molecular level has greatly expanded. However, optimal
incorporation of molecular markers into clinical care is
controversial. We briefly review the potential utility of
molecular stratification in refining histologic diagnosis,
prognosis, and treatment decisions, focussing on 1p/19q co-
deletion, MGMT promoter methylation, EGFR mutations,
and IDH mutation. The most recently discovered IDH
mutation is a striking example of a rapid implementation of
a molecular marker for prognostication into common
clinical use.
Keywords Glioma .MGMT.Molecular . 1p19q .
Prognostic . Predictive . EGFR . IDH
Introduction
Adult patients with malignant gliomas almost always
ultimately die from their disease. However, if the biology
of gliomas is elucidated, targeted therapies may allow
individualized patient care tailored to tumor biology. For
example, the last several years have led to promising
discoveries allowing molecular sub-classification of high-
grade gliomas [1, 2] that can also supplement classic
histology.
At this time, we rely primarily on clinical factors such as
age, Karnofsky performance status, tumor size, presence of
neurologic symptoms, and extent of resection to inform
prognosis. These parameters and others have been used to
identify prognostically important classes using recursive
partitioning analysis (RPA) for patients with anaplastic
astrocytomas and glioblastomas (GBMs) [3, 4]. They have
been proven useful and were validated by subsequent
glioma trials both at diagnosis and recurrence [4, 5]. They
are critical stratification factors for randomized phase III
clinical trials and for interpretation of single arm phase II
studies to ensure valid historic controls are used although
selection bias cannot be completely eliminated, as would a
control arm in a randomized trial. However, molecular
stratification is also emerging as key to ensure trials with
multiple arms are adequately balanced, and that results of
single arm studies are not misinterpreted.
Currently there is no molecular marker in neuro-
oncology to accurately predict drug responsiveness of
tumors as stringently as the oncogene BCR-ABL in chronic
myelogenous leukemia. However, MGMT promoter meth-
ylation predicts enhanced sensitivity to temozolomide
chemotherapy, and some data suggest that response to
epidermal growth factor receptor (EGFR) inhibitors
depends on mutations in EGFR [6, 7]. Advances in
understanding glioma biology may, therefore, assist in
histologic classification, prognostication, and treatment
decisions.
In relation to these clinical issues, this review will focus
on MGMT promoter methylation, 1p19q co-deletion, iso-
citrate dehydrogenase (IDH) 1/2 mutation, and EGFR
amplification/mutation (Table 1).
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MGMT promoter methylation
The importance of silencing DNA repair pathways, espe-
cially the DNA-repair enzyme AGT (O6-alkylguanine DNA
alkyltransferase) encoded by the gene MGMT (O6-methyl-
guanine-DNA-methyltransferase), has been the subject of
substantial debate in recent years. A methylated (and
thereby silenced) MGMT promoter is observed in many
cancers, including low-grade gliomas (up to 93% in one
series) [8], and in 45% in a series of GBMs [9].
The landmark European Organisation for Research and
Treatment (EORTC)-National Cancer Institute of Canada
(NCIC) study demonstrated a survival advantage from the
addition of the DNA methylating agent temozolomide to
radiotherapy [10]. A companion molecular study of
archival pre-treatment tissue [9], and 5-year follow up data
[11] also demonstrated that patients with MGMT methylat-
ed tumors derive the most benefit from temozolomide. For
example, median survival was longer by 8.1 months in
methylated cases (23.4 for radiotherapy and temozolomide
versus 15.3 for radiotherapy alone); by contrast, there was
less than 1-month difference in median survival in
unmethylated cases (12.6 versus 11.8) [11]. However, it
remains unclear whether a more favorable outcome in
MGMT methylated cases results from enhanced sensitivity
to alkylating agents or rather reflects a broader advanta-
geous molecular profile of which MGMT methylation is
one part.
The “broader view” is supported by the observations that
methylated tumors also draw benefit from radiation therapy
alone [9–14] or from non-alkylating drugs [15]. For
example, survival following radiotherapy alone in the
EORTC-NCIC study was 15.3 months in methylated cases
versus 11.8 months in unmethylated cases. It is possible
that temozolomide administered for disease progression
after radiotherapy in temozolomide-naïve patients may
explain these results, at least in part. However, they also
suggest that our understanding of the mechanism by which
MGMT promoter methylation affects outcome is incomplete
at this time. In addition, MGMT protein expression
(technically AGT but MGMT is now widely adopted as
the nomenclature for both gene and protein product) [16]
does not correlate with temozolomide efficacy [17, 18],
probably because of contamination by normal tissue, but
also suggesting a more complex mechanism than simply
MGMT gene silencing by promoter methylation. Finally,
patients with tumors that do not exhibit a methylated
promoter also survive longer following treatment with
temozolomide and radiotherapy than radiotherapy alone at
diagnosis [11].
Therefore, it appears that MGMT methylation status is
prognostic for survival regardless of therapy, and likely at
least partially predictive of enhanced sensitivity to DNA
alkylating chemotherapeutics. This has led some to advo-
cate radiotherapy alone, without temozolomide, in patients
with newly diagnosed GBM harboring unmethylated
disease. It may be appropriate to modify therapy based
on MGMT status in a clinical trial, such as restricting entry
to those with or without MGMT methylated tumor [15] as
in the CENTRIC study (EORTC 26071-22072,
NCT00689221). However, it should be noted that the
current standard of care outside of a trial is radiotherapy
and temozolomide regardless of MGMT status.
In the unmethylated setting, whether prolonged exposure
to alkylating agents might deplete MGMT and thereby
overcome MGMT mediated DNA repair mechanisms is an
area of active investigation. Various alternative temozolo-
mide dosing schedules are under investigation [19] some of
which appear promising in early trials for newly diagnosed
[20] and recurrent GBM [21–23]. These may prove
superior to standard dosing, especially in cases without
MGMT methylation, inferior, or equivalent with more or
Table 1 Frequency and possible role of tumor markers in glioma
Molecular marker WHO II WHO III WHO IV Diagnostic role Prognostic in
low grade anaplastic glioblastoma
MGMT promoter
methylation
~93% [8] ~50–80% [13, 14] ~45% [9] WHO II–IV [9–15, 18]
~40% 1°GBM
~70% 2°GBM
1p19q co-deletion ~85% [30] ~65% [30] ~5–25% [42–45] WHO III oligodendroglial
subtype [33–39]
WHO II–III
[14, 40, 46–48]
WHO IV unclear
[18, 43, 45, 49]
IDH 1/2 mutation ~70–80 % [64, 65] ~65–70% [64–66] <10% 1° GBM [64] WHO I versus II [70] WHO II–IV [14, 66, 71]
>80% 2° GBM [64]
EGFR amplification/
mutation
~10% [78] ~45% [2] WHO III astrocytic
subtype [74, 75]
WHO IV unclear
[18, 76–78]
EGFR vIII 1° GBM [73]
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less toxicity. However, MGMT is not the only DNA repair
mechanism of importance in gliomas. Accordingly, it is
notable that the British Medical Research Council (MRC)
trial BR12 of chemo-naïve patients with recurrent high-
grade gliomas did not demonstrate superior efficacy with
dose-intense temozolomide (100 mg/m2, 21/28) versus
standard dosing (200 mg/m2, 5/28) [24]. In fact, unexpect-
edly, progression-free survival favored standard dosing (p=
0.023), and there was a trend toward favoring survival [24]
(Michael Brada, personal communication). Radiation Ther-
apy Oncology Group (RTOG) trial 0525 is a phase III study
that randomized patients with newly diagnosed GBM to
initiate either standard or dose-intense temozolomide after
radiotherapy. Accrual is complete and results are pending.
Another randomized trial dealing with a similar issue in
recurrent GBMs is still accruing patients (DIRECTOR trial,
conducted by the Neurooncology Working Group (NOA) of
the German Cancer Society).
Elsewhere in this issue, Riemenschneider et al. [25]
discuss analysis of and controversies surrounding MGMT
methylation in more detail.
1p19q co-deletion
Approximately 5–10% of all primary brain tumors are
oligodendrogliomas [26]. Loss of genetic material on the
short (p) arm of chromosome 1 and the long (q) arm of
chromosome 19, so-called chromosome 1p19q co-deletion,
was first reported as an observation in oligodendroglial
tumors in 1994 [27]. Cairncross et al. then reported
chemosensitivity in patients with anaplastic oligodendro-
gliomas harboring deletion of 1p and particularly co-
deletion of 1p and 19q [28]. Further study ensured, and it
is now known that chromosomal loss results from an
unbalanced translocation [29]. Nearly 85% of low-grade
oligodendrogliomas and 65% of anaplastic oligodendro-
gliomas harbor 1p19q co-deletion [30]. The higher
frequency in lower grade tumors suggests deletion is an
early event in tumor formation (J. Gregory Cairncross,
personal communication). Indeed, observational studies
suggest that co-deletion may be more common in cases of
anaplastic oligodendroglial tumors with a prior history of
low-grade glioma [31].
1p19q deletion status is frequently used to refine
histologic diagnoses. The current World Health Organiza-
tion (WHO) classification of gliomas is based on histopa-
thology which divides gliomas into astrocytomas,
oligodendrogliomas, and mixed oligo-astrocytomas as the
most common subtypes [32]. However, histopathology
alone does not identify molecular subtypes. For example,
there is high inter-observer variation in diagnosing oligo-
dendrogliomas [33], and expert panels often disagree [34–
38]. As 1p19q co-deletion is most common in oligoden-
drogliomas, it is often used in the community and at
academic centers to support a diagnosis of oligodendro-
glioma in cases with ambiguous histology [39]. However,
molecular analysis alone is insufficient for diagnosis, and
should be used to complement rather than replace classic
histopathology [34, 36, 39, 40]. Approximately 20% [41] of
otherwise WHO grade IV tumors (GBMs) contain oligo-
dendroglial features (termed GBM-O according to the most
recent 2007 WHO classification) [32]. GBM-O likely
harbors a higher frequency of 1p and /or 19q deletion than
purely astrocytic GBM, but the reported frequencies vary
from approximately 5% [42, 43] to approximately 25% [44,
45].
1p19q co-deletion is prognostic in anaplastic gliomas,
validated in three randomized trials [14, 46, 47]. As a
consequence, the two open phase III trials for anaplastic
gliomas use both histology and deletion status as eligibility
criteria. EORTC 26053-22054 (Concurrent and Adjuvant
Temozolomide Chemotherapy for patients with NON-
1p19q deleted anaplastic glioma [CATNON] intergroup
study) randomizes patients without 1p19q co-deleted
anaplastic gliomas to radiotherapy with or without concur-
rent and/or adjuvant temozolomide. NCCTG N057 (for
1p19q co-deleted tumors, also called CODEL) will ran-
domize patients with 1p19q co-deleted anaplastic gliomas
to radiotherapy, radiotherapy with concurrent and adjuvant
temozolomide, or temozolomide. 1p19q co-deletion is
likely also prognostic for low-grade gliomas, but the data
are less well defined. One study suggested that chromo-
some 1p status is a significant prognostic marker in low-
grade gliomas regardless of histologic subtype [48]. A
recently completed randomized trial of the EORTC 22033-
26033/NCIC in patients with WHO grade II gliomas
stratified tumors by 1p status and will provide more
information. There is inconsistency regarding the prognos-
tic value of 1p and 19q deletion in GBMs with oligoden-
droglial features. For example, one study suggests that
long-term survivors from GBM do not commonly harbor
1p19q co-deletion [49]. However, 1p and 19q co-deletion is
uncommon in GBMs as is long-term survival, making it
difficult to address this issue definitively with sufficiently
powered studies when clinical prognostic factors (e.g., age,
extent of resection) are also considered [43, 45]. The
variability observed in both deletion frequency and prog-
nostic importance across studies may be explained at least
in part by the histologic overlap between GBM-O and
anaplastic oligodendroglioma, causing inclusion criteria
inconsistencies. Finally, the prognostic significance of 19q
deletion without 1p deletion, 1p deletion without 19q
deletion, and 1p19q co-deletion with other chromosomal
abnormalities (such as 10q deletion or chromosome 7 gain)
is not definitively understood with the existing data.
Targ Oncol (2010) 5:201–210 203
Although 1p19q co-deletion is clearly correlated with
longer survival, it remains debated whether 1p19q status
should alter therapy. Of note, the favorable prognosis
associated with 1p19q co-deletion in oligodendroglial
tumors may be reduced if no post-operative therapy is
administered. In one study, after surgery alone, combined
1p19q co-deletion was not prognostic for progression-free
survival using multivariate analysis in a small number of
patients with WHO grade II and III tumors [50]. This
observation suggests that the mechanism by which 1p19q
co-deletion contributes to tumor biology may be through
reduced expression of chemotherapy and/or radiotherapy
resistance factors. Therefore, 1p19q co-deletion may im-
prove outcome only if surgery is followed by further
therapy. However, others have reported opposing results
[51], and selection bias is a potential confounder. Moreover,
almost no neuro-oncologists would advocate observation
for anaplastic oligodendroglial tumors regardless of 1p19q
status [52].
Regarding definitive therapy, the standard therapy for all
WHO grade III–IV tumors, including anaplastic oligoden-
drogliomas, before the discovery of 1p19q co-deletion was
radiotherapy alone. This resulted from early multicenter
studies conducted in the 1970s comparing radiotherapy
with or without chemotherapy against chemotherapy alone
or supportive care only [53, 54]. These studies addressed
whether radiotherapy improves survival in high-grade
gliomas, as that was debated at the time. Although
radiotherapy was clearly demonstrated as beneficial, these
early studies did not distinguish among various high-grade
glioma histologies and almost all patients enrolled had
astrocytomas [55]. However, by the late 1980s and early
1990s reports emerged of exquisite chemosensitivity among
both recurrent [56, 57] and newly diagnosed oligodendro-
gliomas [57, 58], especially those harboring 1p19q co-
deletion [59]. Therefore, EORTC 26951 [47] and RTOG
9402 [46] were conceived as phase III randomized trials to
evaluate the efficacy of adding chemotherapy (using
procarbazine, lomustine, and vincristine collectively called
PCV) to radiotherapy in comparison to radiotherapy alone
(then the standard). Both trials demonstrated, somewhat
surprisingly, that overall survival was not prolonged by
incorporating PCV into the up-front regimen, either
immediately before [46] or after [47] radiotherapy. How-
ever, both trials also collected tissue used for 1p19q
analysis, and both demonstrated prolonged progression-
free survival following combined therapy in 1p19q co-
deleted cases. The toxicity of PCV is substantial, and the
intensified PCV regimen in RTOG 9402 (shorter cycles
with higher doses of each agent) resulted in one fatal
toxicity [46]. Accordingly, without a survival advantage, it
is unclear whether the benefit of a longer progression-free
interval outweighs the risks of potential toxicity. Of note,
however, the median survival in the 1p19q co-deleted
cohort was not reached for patients treated with radiother-
apy and intensive-PCV in RTOG 9402 as the survival
curves began to separate [46], and further maturity of the
data may well demonstrate a survival advantage on the
experimental arm [60]. Longer follow up has not been
conducted yet for EORTC 26951 (Martin J. van den Bent,
personal communication).
Finally, the median survival of patients with anaplastic
oligodendrogliomas is approximately 5 years [26], and
longer for those harboring 1p19q co-deletion. This is
superior to the prognosis for astrocytomas of the same
histologic grade [26]. Therefore, there is a small but real
risk of delayed neuro-cognitive decline associated with
early radiotherapy for anaplastic oligodendrogliomas, sim-
ilar to that observed in long-term survivors of low-grade
gliomas [61] or brain metastases [62]. This leads many
neuro-oncologists, up to 42% in one survey, to advocate
chemotherapy alone for newly diagnosed anaplastic oligo-
dendrogliomas harboring 1p19q deletion [52]. A retrospec-
tive study suggests deferring radiotherapy until first or later
progression is reasonable in such patients [31]. A phase III
prospective study by the Neurooncology Working Group
(NOA) of the German Cancer Society (NOA-04) also
suggests that initial chemotherapy is not inferior to
radiotherapy in anaplastic gliomas [14] although the study
design has been questioned [63]. The CODEL study will
incorporate quality of life/neuro-cognitive endpoints to
address some of these issues.
IDH 1/2 mutation
Sequencing of the genome recently identified mutations in
the isocitrate dehydrogenase 1 and 2 gene (IDH 1/2) that
occur in the majority of WHO grade II–III gliomas and
secondary GBMs [64, 65], all of which harbor a better
prognosis compared to wild type cases [66]. A high
frequency in low-grade gliomas and secondary GBMs
suggests a role in early tumor development [64] similar to
1p19q co-deletion in oligodendrogliomas. Therefore, it is
not surprising that all 1p19q-deleted tumors apparently also
harbor IDH1 or IDH2 mutations [67]. IDH appears to
function as a tumor suppressor when inactivated through
mutation [68], which causes the IDH enzyme to lose its
ability to catalyze conversion of isocitrate to alpha-
ketoglutarate and induces HIF1-alpha (hypoxia-inducible
factor), which triggers the angiogenic process. However,
the precise mechanism of its effect on tumor biology is
currently unclear [68, 69].
IDH mutations occur in WHO grade II–IV tumors, and
are not currently used to supplement classic histology. Yet,
pilocytic astrocytomas (WHO grade I) that are potentially
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curable by complete resection, rarely harbor IDH muta-
tions. Occasionally they are difficult to distinguish histo-
logically from diffuse infiltrating WHO grade II
astrocytomas (with almost no curative potential). BRAF
abnormalities that occur in 60–80% of pilocytic astrocyto-
mas and almost never in diffuse astrocytomas seem to be
helpful in this regard [70].
More importantly, the value of IDH 1/2 mutations relates
to prognosis, as demonstrated in the German NOA 04 trial
where patients with WHO grade III gliomas received
primary radiotherapy or primary chemotherapy followed
by cross-over at progression [14] and EORTC 26951 in
which patients with anaplastic oligodendroglial tumors
received primary radiotherapy alone or combined with
PCV [71]. Both studies demonstrated longer survival
correlated with IDH mutation. A French series also
demonstrated that IDH1 mutations independently predicted
longer survival for patients with both low- and high-grade
gliomas [66]. Others reported analogous prognostic value
across glioma grades [64], and also observed that 100% of
1p19q deleted tumors harbor mutations in IDH1 or IDH2
[72].
At this time, IDH mutations do not appear predictive for
outcome to a specific therapy. However, our understanding
of the interplay between IDH mutation and oncogenesis is
currently limited.
EGFR mutation
EGFR was among the first cell-surface glycoproteins
recognized as amplified and re-arranged in GBM and
acting as an oncogene. Many GBMs exhibiting EGFR
amplification have EGFR mutations, most commonly the
variant 3 (EGFRvIII) (approximately 40%), which is truly
tumor-specific and results from deletion of exons 2–7
leading to constitutive receptor activity [73].
EGFR amplification and mutation define a distinct
subset of tumors. EGFR abnormalities are typically
associated with GBM and anaplastic astrocytoma rather
than oligodendrogliomas [74, 75]. This observation may
help to refine histologic diagnosis in ambiguous cases.
The prognostic relevance of EGFR amplification and
EGFRvIII mutation in GBM remain controversial. Tumors
expressing EGFRvIII behaved more aggressively in one
study, but only when other prognostic factors were
considered [76]. In a population-based study, the presence
of EGFR amplification did not significantly affect survival
of patients with GBM at any age [77]. The prognostic
importance of EGFR abnormalities is inconclusive at this
time, with conflicting data as reviewed elsewhere [77, 78].
Similarly, whether therapy should be tailored based on
presence or absence of EGFR amplification or mutation is
an area of active study. Available data is insufficient to
guide management decisions outside of a clinical trial.
EGFRvIII-expressing tumor cells are an ideal target for
passive and active immunotherapy as the mutation does not
occur in normal glia. Trials with various vaccination
approaches are underway with promising early results
[79], but selection bias (i.e., exclusion of patients with less
than gross-total resection) and accrual are challenges to
interpretation and study completion.
EGFR tyrosine kinase inhibitors (TKIs) have been
studied in multiple trials, typically for recurrent GBM with
almost universally negative results [80–85]. Poor efficacy
may result from inadequate drug penetration into brain
tumor tissue of erlotinib at standard dosing [86, 87].
Gefitinib may have superior penetration [86, 88] but is
unavailable in the United States. Lapatinib also may
become sequestered in brain tumor tissue [89], but has
been studied in gliomas less extensively than other EGFR
TKIs.
It is controversial whether EGFR amplification or
mutation predicts sensitivity to EGFR TKIs, presuming
adequate drug delivery. One retrospective analysis of pre-
treatment tissue from patients prospectively enrolled in
multicenter phase I/II studies demonstrated that EGFRvIII
mutation in the setting of retained expression of its
downstream mediator, phosphatase and tensin homolog on
chromosome ten (PTEN), strongly predicted radiographic
response of recurrent malignant gliomas to erlotinib and
gefitinib [6]. Another study similarly demonstrated EGFR
overexpression/amplification and reduced AKT activity
(which results from PTEN retention) were predictive of
erlotinib response [90]. A case report also suggests that this
molecular signature is predictive of response [91]. Howev-
er, others have questioned these results [92]. For example, a
prospective trial (EORTC 26034) did not find EGFRvIII or
PTEN to correlate with clinical benefit [93]. The discrep-
ancy in findings may result from lack of uniformity in
defining both clinical efficacy (e.g., 6-month progression-
free survival versus response rate as well as differing
criteria for designation of radiographic response) and
scoring of EGFR/PTEN anomalies in human tumor
samples. In addition, all of these studies used a similar
design—to enroll patients without regard to molecular
information and then retrospectively correlate EGFR and
PTEN anomalies with clinical outcome. The frequency of
EGFRvIII and PTEN co-expression is so low (approxi-
mately 5–10% of cases in our experience) that a prospective
trial exclusively for patients harboring tumors with such a
molecular profile is impractical. Moreover, neither EGFR
amplification, nor EGFRvIII mutational analysis, nor PTEN
analysis is routinely available at most centers. A planned
prospective study of EGFR tyrosine kinase inhibition will
require the presence of EGFRvIII mutation for eligibility
Targ Oncol (2010) 5:201–210 205
and use a different erlotinib dosing schedule than previ-
ously administered [87] for gliomas to potentially overcome
resistance mediated by PTEN loss.
Conclusions
Diagnostic and prognostic markers are increasingly imple-
mented in neuro-oncology as decision-making tools toward
more objective classification of gliomas, to prognosticate,
and to guide therapy. 1p19q co-deletion supplements classic
histology to clarify a diagnosis of oligodendroglioma. By
contrast, EGFR abnormalities are most common in astro-
cytomas. The prognostic value of various markers is well
established, although their predictive value in guiding
specific therapy is an area of active research. For example,
MGMT promoter methylation, 1p19q co-deletion, and IDH
1/2- mutation each indicate a more favorable disease
outcome independent of the type of therapy. This holds true
for WHO grade II–IV gliomas, except perhaps for an unclear
significance of 1p19q co-deletion in GBMs. In clinical trials,
accrual must be stratified accordingly in order to avoid
biasing results.
Linkage of “favourable prognosis” markers, or a
“hierarchy”, is still not well understood. However, 1p19q
co-deletion seems to occur exclusively of EGFR abnormal-
ities [75] but co-segregates with IDH mutation [67].
Moreover, in oligodendroglial tumours there is a strong
correlation between the presence of MGMT promoter
methylation, 1p19q co-deletion, and IDH 1/2 mutation, at
least in anaplastic disease [13, 14, 71, 72]. Data in GBMs
are less clear [18]. Whether the underlying mechanisms act
independently or together remains to be investigated.
It is tempting to speculate that patients with tumors that
harbor poor prognostic molecular markers (e.g., unmethy-
lated MGMT promoter, wild type IDH1 and IDH2, lack of
1p19q deletion) should be treated more intensely. One
example is incorporation of bevacizumab, approved for
treatment of recurrent GBM in the United States and
Switzerland, into the treatment administered at diagnosis,
although benefit at recurrence is still debated [94]. Ongoing
GBM trials (RTOG 0825, AVAGLIO) will address this issue.
However, more is not necessarily better, and it is unclear
whether more aggressive therapy improves survival for such
patients or only risks additional toxicity [95]. For example, in
anaplastic oligodendroglial tumors without 1p19q co-deletion,
there was neither a progression-free survival nor overall
survival benefit for radiotherapy and PCV versus radiotherapy
alone in one randomized phase III trial (RTOG 9402) [46].
Therefore, to date there is no validated predictive
biomarker to accurately guide a clinician in deciding
treatment in routine practice. However, this remains an
area of active investigation and multiple clinical trials are
incorporating molecular information into their design,
either as stratification factors to balance treatment arms in
randomized studies, or as eligibility criteria.
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